The recent development and clinical success of the BCL-2 inhibitor venetoclax (ABT-199) as treatment for chronic lymphocytic leukemia [54], acute myeloid leukemia [55] and other hematologic malignancies has shown that targeting apoptosis directly has the potential to significantly improve patient outcomes. This evidence concerns the gene BCL2 and hematologic disorder.